Join Free For Buyer|Sign In

Professional Online Trade Platform for API, Preparation and Pharmaceutical Machinery and Equipment_EN-CPhI.cn

You are here:  Home >>  News >>  Editors’ Picks >>  Sales of Osimertinib Approaching RMB 2 Billion in China in 2018

Sales of Osimertinib Approaching RMB 2 Billion in China in 2018

April 03, 2019 By Caicai

The third generation has become the R&D hotspot of the giants. How Hot is the Third-generation EGFR-TKI?

Sales of Osimertinib Approaching RMB 2 Billion in China in 2018

Osimertinib, the only third-generation EGFR-TKI marketed in the world

Developed by AstraZeneca, osimertinib (trade name: Tagrisso, code: AZD9291) is the only third-generation EGFR-TKI marketed in the world at present, which mainly bind to the small T790M mutation domain through a smaller binding region, to reach the treatment effect. Its approval process is as shown below:

Nov. 2015

Osimertinib received FDA’s accelerated approval to become the first targeted drug marketed for patients with T790M mutation-positive NSCLC who have progressed on or after EGFR-TKI therapy

Mar. 2017

Osimertinib received CFDA’s approval be formally marketed in China for adult patients with T790M mutation-positive locally advanced or metastatic NSCLC, as detected by test, who have progressed on or after EGFR-TKI therapy, being the first tumor drug approved in China for EGFR T790M mutation-positive locally advanced or metastatic NSCLC

Sep. 2017

NCCN guideline recommends osimertinib to be used as a first-line therapy for patients with locally advanced or metastatic EGFR mutation-positive NSCLC

Apr. 2018

FDA approved osimertinib as first-line therapy for patients with EGFR-mutation metastatic NSCLC

June 2018

EMA approved osimertinib as first-line therapy for patients with EGFR-mutation metastatic NSCLC

Osimertinib has been approved in more than 80 countries including the U.S., EU, Japan, and China as a second-line therapy for patients with T790M resistance mutation NSCLC; and it has been approved in more than 60 countries as a first-line therapy since Apr. 2018, and it is expected to be approved in China in the first half of 2019.

Global sales doubled in 2018, sales in China of nearly RMB 2 billion

Osimertinib has emerged in the competition with each generation of TKI and its sales have rapidly grown, owing to the differentiation competitive advantage in T790M resistance mutation and outstanding clinical efficacy. Global sales of osimertinib reached USD 1.86 billion in 2018, growing by 95%; it has become the best-selling tumor drug of AstraZeneca and the drug with the second highest sales thereof, and it may become the best-selling drug of AstraZeneca in 2019, which is mainly because of its ascending into a first-line therapy and deeper penetration into more markets as a second-line therapy. Osimertinib’s sales reached RMB 1.85 billion in the first three quarters of 2018 in China, and its sales of the year approached RMB 2 billion.

 

2016年、2017年、2018年

2016, 2017, 2018

 (Source: Annual reports of the company)

Osimertinib has been included into Category B varieties of medical insurance in China in Oct. 2018, with the medical insurance payment standard of RMB 510 (80mg/tablet) and RMB 300 (40mg/tablet), and restricted coverage of adult patients with EGFR T790M mutation-positive locally advanced or metastatic NSCLC, as detected by test, who have progressed on or after EGFR-TKI therapy.

Read More:

How Hot is the Third-generation EGFR-TKI?

Register as Visitor to CPhI China 2019!

Register as Visitor to CPhI China 2019!

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.

 

Readers'Comments
Add a comment
Click here to Login or to Register for free. You will be taken back to your selected item after Login/Registration.
More>> MarketNews
More>> Editors’Picks
More>> TopStories
More>> HotTags
Follow Us
CPhI Online Trade Platform: Worldwide|English|中国站
Customer Service:  86-400 610 1188 (9: 00-18: 00, Mon-Fri)
About Us| Contact Us| Terms of Services| Privacy Policy| Intellectual Property Statement| Links | Site Map
Copyright 2006-20 Shanghai UBM Sinoexpo International Exhibition Co Ltd (All Rights Reserved). ICP 05034851-53
网页对话
live chat